Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Episodic Migraine Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

10 recruiting trials for Episodic Migraine. Eligibility criteria explained in plain English.

TrialFinderData lists 10 Episodic Migraine clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 3 is the largest group at 67% (4 studies); the largest phase groups are Phase 3: 4, Phase 2: 2.

Research is led by IRCCS National Neurological Institute "C. Mondino" Foundation (2), Ipsen (1), Hospital Universitari Vall d'Hebron Research Institute (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Placebo (other, 4 trials), followed by IPN10200, IPN10200 dose A.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
10
Total Trials
10
Recruiting Now
4
Phase 3 Trials
9
Sponsors

Track Episodic Migraine trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 2NCT06625060

A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity...

Sponsor: IpsenEnrolling: 64120 locations
RECRUITINGNCT07159750

Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide...

Sponsor: Hospital Universitari Vall d'Hebron Research InstituteEnrolling: 70020 locations
RECRUITINGPhase 3NCT05711394

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants...

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light...

Sponsor: AbbVieEnrolling: 45020 locations
RECRUITINGNCT06562413

Searching for Novel Biological Phenotypes in Migraine Patients Resistant to Treatments

The investigators aim to define the neurofunctional phenotype of migraine patients who did not respond to at least 3 preventive treatments, including monoclonal antibodies (mAbs)...

Sponsor: IRCCS National Neurological Institute "C. Mondino" FoundationEnrolling: 1001 location
RECRUITINGNCT07103694

i-NEED: NEw migrainE Drugs Database

Approved by the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) starting in 2018, anti-CGRP monoclonal antibodies (anti-CGRP mAbs) represent the first...

Sponsor: IRCCS San Raffaele RomaEnrolling: 26412 locations
RECRUITINGPhase 3NCT07496034

Efficacy of Gou-Teng-San (GTS) in Patients With Episodic Migraine

The goal of this study is to learn whether Gou-Teng-San (GTS), a traditional herbal medicine, is effective and safe for adults with episodic migraine. In this double-blind...

Sponsor: Tsai, Chueh-Yi, MDEnrolling: 401 location
RECRUITINGPhase 3NCT05897320

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.

Sponsor: H. Lundbeck A/SEnrolling: 31520 locations
RECRUITINGNCT06562400

Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments

Primary working hypothesis is that NON-responders to mAbs bear a dysfunction of the endocannabidiome system (eCBome), as suggested by pre-clinical and clinical data by our group....

Sponsor: IRCCS National Neurological Institute "C. Mondino" FoundationEnrolling: 451 location
RECRUITINGPhase 3NCT07018700

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

In this clinical trial, participants with episodic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change...

Sponsor: Merz Therapeutics GmbHEnrolling: 99020 locations
RECRUITINGPhase 2NCT05734625

Efficacy of Nerve Blocks for Episodic Migraine

The purpose of this study is to see how well blocking two to ten of the scalp nerves (that give feeling to the scalp and are painful during migraine headaches) with bupivacaine...

Sponsor: Mayo ClinicEnrolling: 601 location

Frequently Asked Questions

There are currently 10 clinical trials for Episodic Migraine, with 10 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Episodic Migraine, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 4 Phase 3 trials for Episodic Migraine, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.